Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP839346.RAb9llGH1iwLU0_199Bip0kJBF_s7ABVop5r6Pu8OyGjE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP839346.RAb9llGH1iwLU0_199Bip0kJBF_s7ABVop5r6Pu8OyGjE130_assertion type Assertion NP839346.RAb9llGH1iwLU0_199Bip0kJBF_s7ABVop5r6Pu8OyGjE130_head.
- NP839346.RAb9llGH1iwLU0_199Bip0kJBF_s7ABVop5r6Pu8OyGjE130_assertion description "[Therefore, MHC II NSCLC vaccines expressing a single HLA-DR allele activate NSCLC-specific CD4(+) T cells that react with the 3 major classes of NSCLC, and the antigens recognized by the activated T cells are presented by several common HLA-DR alleles, suggesting that the MHC II NSCLC vaccines are potential immunotherapeutics for a range of NSCLC patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP839346.RAb9llGH1iwLU0_199Bip0kJBF_s7ABVop5r6Pu8OyGjE130_provenance.
- NP839346.RAb9llGH1iwLU0_199Bip0kJBF_s7ABVop5r6Pu8OyGjE130_assertion evidence source_evidence_literature NP839346.RAb9llGH1iwLU0_199Bip0kJBF_s7ABVop5r6Pu8OyGjE130_provenance.
- NP839346.RAb9llGH1iwLU0_199Bip0kJBF_s7ABVop5r6Pu8OyGjE130_assertion SIO_000772 20473949 NP839346.RAb9llGH1iwLU0_199Bip0kJBF_s7ABVop5r6Pu8OyGjE130_provenance.
- NP839346.RAb9llGH1iwLU0_199Bip0kJBF_s7ABVop5r6Pu8OyGjE130_assertion wasDerivedFrom befree-20140225 NP839346.RAb9llGH1iwLU0_199Bip0kJBF_s7ABVop5r6Pu8OyGjE130_provenance.
- NP839346.RAb9llGH1iwLU0_199Bip0kJBF_s7ABVop5r6Pu8OyGjE130_assertion wasGeneratedBy ECO_0000203 NP839346.RAb9llGH1iwLU0_199Bip0kJBF_s7ABVop5r6Pu8OyGjE130_provenance.